What we deliver
We have long-standing relationships with many clients as trusted advisers to drive and support strategic changes. Often our work is related to the client’s asset portfolio as new indications are evaluated, markets are assessed, and implementation plans are executed. However, equally often, we’re contracted to support the different phases in the partnering process with licensees, acquirers or investors. We adapt to the clients’ needs, which means that our results have been delivered in presentations, investment memos, spreadsheets, prospectuses, fact sheets, business plans, orphan drug designation (ODD) applications, investigational new drug (IND) documentation and many other forms of decision-support material. Just like our clients’ day-to-day activities, our deliveries are rarely standard.
Some past questions from our clients include:
How can we prepare for licensing after our phase 2 data is available?
Who in Scandinavia should we partner with to leverage our I/O strategy?
What preclinical assets in NASH are available for licensing in the Nordic region?
Is it possible to build an orphan drug strategy based on our current animal data?
Should we consider becoming a platform company or stay with our current drug development program?
What oncology player provides the best strategic fit for our cell therapy?
Business plan development to raise clinical phase 3 financing
The CEO of an oncology company needed to attract 100+ MSEK in venture capital to fund its clinical phase 2 development in a new indication.
Opportunity assessment and partnering preparation
A public company wanted to assess its opportunity in inlicensing assets in the immune checkpoint blocker field and wanted to position its cell therapeutic portfolio for partnering its technology with a leading player.